Senti Biosciences, Inc. (SNTI) on Tuesday announced that the FDA has granted Regenerative Medicine Advanced Therapy designation to SENTI-202, its off-the-shelf CAR-NK therapy being developed for relapsed or refractory AML and other hematologic cancers.
This recognition comes from new Phase 1 data that shows the treatment can specifically target leukemic cells without harming healthy stem cells. It follows Senti's earlier Orphan Drug Designation this year.
The company presented updated SENTI-202 data at the 2025 ASH Annual Meeting, and there's an investor webcast lined up for December 9.
SNTI is currently trading at $2.6083, up $0.2183 or 9.13 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Economic News
What parts of the world are seeing the best (and worst) economic performances lately? Click here to check out our Econ Scorecard and find out! See up-to-the-moment rankings for the best and worst performers in GDP, unemployment rate, inflation and much more.
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.